We recently had the pleasure of hosting an intimate dinner alongside the Reuters Pharma Barcelona event, bringing together a selected group of senior leaders from across the pharmaceutical industry. The evening created a space for candid, high-quality dialogue among peers navigating similar challenges and opportunities in a rapidly evolving landscape.
What stood out most was the openness of the conversation and the depth of insight shared across the table. Leaders engaged not only in exchanging perspectives, but in collectively unpacking some of the most pressing topics shaping the future of the industry, from AI adoption and organizational transformation to talent, culture, and compliance. It became clear that gatherings like this serve a broader purpose: they foster meaningful connections while enabling shared learning in a trusted, off-the-record environment.
As the discussion unfolded, several key themes emerged, reflecting both the diversity of organizational experiences and a growing alignment on where the industry is headed.
Key Discussion Themes
1. Current State of AI Adoption: From Experimentation to Enterprise Ambition
Organizations are at varying levels of AI maturity. While many have successfully enabled individual-level adoption, empowering employees with tools to enhance productivity, enterprise-wide scaling remains a challenge.
Key barriers include:
- Fragmentation of use cases across functions
- Data readiness and infrastructure limitations
- Cost considerations, especially when balancing experimentation with measurable ROI
There is a clear shift in focus from isolated pilots toward integrated, enterprise-level AI strategies, though execution remains uneven.
2. From Prompt Engineering to Context Engineering
A notable evolution in how organizations approach AI is underway. The conversation is moving beyond prompt engineering (crafting effective inputs) toward context engineering, ensuring AI systems are grounded in the right data, workflows, and business context.
This shift reflects a growing recognition that sustainable value comes not just from interacting with AI, but from embedding it meaningfully into business processes. This was also a topic discussed during the conference panels.
3. Compliance as Both Constraint and Catalyst
Compliance emerged as a central theme, particularly in regulated environments like pharma. While it can slow down implementation, it is also shaping high-value, controlled use cases, such as:
- Internal task automation
- Knowledge retrieval and synthesis
- Early explorations of agentic AI within governed environments
Organizations are actively balancing innovation with risk management, often erring on the side of caution.
4. AI Adoption as a Top-Down Mandate
Several leaders emphasized that AI adoption is increasingly being driven as a strategic priority from top management. This includes:
- Setting expectations for everyday AI usage
- Encouraging cultural shifts toward experimentation
- Embedding AI into daily workflows rather than treating it as optional
The implication is clear: AI is no longer a side initiative, it is becoming part of how work gets done.
5. Culture, Talent, and Organizational Evolution
The discussion highlighted how company culture and structure significantly influence transformation efforts. Key reflections included:
- A strong commitment to patient-centric decision-making in leading organizations
- The unique mindset required in rare disease spaces, where conventional approaches often fall short
- The evolving expectations placed on teams during organizational transformations, such as acquisitions or global expansion
As part of the conversation, we explicitly asked each participant to share the one thing they love most about their organization. This inquiry was designed to surface authentic views on culture and revealed a consistent sense of openness across the industry.
An additional theme explored was gender balance across the industry. The group discussed the tension between compliance requirements and diversity ambitions versus the reality of available talent in the market. In particular, there was recognition of the higher representation of women in entry-level roles compared to senior leadership, highlighting the need for more deliberate efforts to develop and retain diverse talent pipelines over time.
Leaders shared personal experiences that underscored the importance of adaptability, purpose-driven work, and cross-functional collaboration.
6. “Pharma Is a Small World”
A recurring and more informal theme was the interconnected nature of the industry. Participants frequently discovered shared connections, past colleagues, overlapping organizational histories, and common experiences.
This reinforced the value of such gatherings in strengthening networks and fostering trust across the ecosystem.
Closing Note
The evening reinforced that while organizations are progressing at different speeds, they are largely aligned on the direction of travel: scaling AI responsibly, embedding it into core operations, and navigating transformation with both ambition and care.
Just as importantly, it highlighted the value of bringing the right people together to exchange perspectives in a trusted setting.
